Skip to main content

Table 2 Adverse events of the MPZ group and the IVCY group

From: Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study

Case no.

Group

Adverse events

1

MPZ

None

2

MPZ

2 M: bacterial bronchitis (improved)

3

MPZ

None

4

MPZ

None

5

MPZ

None

6

MPZ

6 M: RS virus infection (improved)

7

MPZ

None

8

IVCY

1 M: cytomegalovirus infection (hospitalization treatment, improved)

1.5 M: purulent arthritis (hospitalization treatment, discontinuation of IVCY)

9

IVCY

3 w: candidemia (death, discontinuation of IVCY)

10

IVCY

None

11

IVCY

None

12

IVCY

2 M: cytomegalovirus infection (hospitalization treatment, improved)

3 M: Aspergillus pneumonia, nocardia pneumonia (hospitalization treatment, improved)

13

IVCY

None

14

IVCY

1.5 M: cytomegalovirus infection (hospitalization treatment, improved)

2 M: liver dysfunction (discontinuation of IVCY)

15

IVCY

None

16

IVCY

1 M: cytomegalovirus infection (hospitalization treatment, improved)

1 M: liver dysfunction (discontinuation of IVCY)

17

IVCY

None

18

IVCY

None

19

IVCY

2 w: cardiac dysfunction (discontinuation of IVCY)

20

IVCY

4 M: bacterial bronchitis (improved)

  1. MPZ mepolizumab, IVCY intravenous cyclophosphamide, M month, w week